[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc (LSE/NYSE: HLN) disclosed a notification under the UK Market Abuse Regulation for a transaction by a Person Discharging Managerial Responsibilities (PDMR). The Company received the notice on 10 September 2025 and reported an executed trade of 34 matching shares at a price of £3.6182 per share. The filing is a routine regulatory disclosure of insider dealing activity and includes the Company’s principal office address in Weybridge, Surrey.

The document also lists Haleon’s consumer brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, and directs readers to www.haleon.com for more information. The filing contains transaction detail limited to volume and price; other typical fields are present in template form but not populated with additional substantive data.

Positive

• Regulatory compliance: Company disclosed a PDMR transaction in accordance with the UK Market Abuse Regulation.
• Transaction detail provided: The filing specifies the exact volume (34 matching shares) and price (£3.6182), enabling market transparency.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine insider transaction disclosure; meets UK MAR/PDMR reporting requirements with basic volume and price detail.

The filing is a standard Form 6-K notice describing a PDMR transaction received on 10 September 2025. It provides the essential details required for market transparency: the number of matching shares traded (34) and the trade price (£3.6182). From a governance perspective, timely disclosure of insider trading maintains regulatory compliance and investor transparency. The filing contains limited additional information and appears mechanistic rather than signaling any corporate governance change.

Securities Analyst

TL;DR: Minor insider share transaction disclosed; immaterial to company fundamentals given small volume reported.

The reported transaction—34 matching shares at £3.6182—represents a very small nominal value trade relative to a public company and thus is unlikely to be material to investors or affect market valuation. The report complies with disclosure norms but lacks context such as aggregate holdings before/after the trade or the PDMR identity. No earnings, debt, or operational metrics are provided, so there is no direct impact on financial analysis from this filing alone.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	10 September 2025 - “Director/PDMR Shareholding”

99.1

​Haleon plc: Director/PDMR Shareholding

​

10 September 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").

On 10 September 2025, the Company received notification of the following transaction as detailed below.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Adrian Morris
2	Reason for the notification
a)	Position/status	General Counsel - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	GB00BMX86B70
	b)	Nature of the transaction	Acquisition of Partnership Shares and award of Matching Shares under the Company's Share Reward Plan
	c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£3.6182	34
			£Nil	34 (Matching Shares)
d)		Aggregated information
	- Aggregated volume	68
	- Price
	e)	Date of the transaction	9 September 2025
	f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Tamara Rogers
2	Reason for the notification
a)	Position/status	Chief Marketing Officer - PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Haleon plc
b)	LEI	549300PSB3WWEODCUP19
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	GB00BMX86B70
	b)	Nature of the transaction	Acquisition of Partnership Shares and award of Matching Shares under the Company's Share Reward Plan
	c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£3.6182	34
			£Nil	34 (Matching Shares)
d)		Aggregated information
	- Aggregated volume	68
	- Price
	e)	Date of the transaction	9 September 2025
	f)	Place of the transaction	London Stock Exchange (XLON)

Amanda Mellor

Company Secretary

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 10, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What PDMR transaction did Haleon (HLN) disclose on 10 September 2025?

The Company disclosed a PDMR transaction of 34 matching shares executed at a price of £3.6182 per share.

Does the Form 6-K identify the individual PDMR who traded HLN shares?

No. The filing provides the transaction volume and price but does not name the individual PDMR in the disclosed text.

Is this Haleon disclosure a routine regulatory filing?

Yes. The notice was made in accordance with the UK Market Abuse Regulation for Transactions by Persons Discharging Managerial Responsibilities.

Where can I find more information about Haleon’s business and brands?

The filing lists key consumer brands and directs readers to www.haleon.com for additional company information.

Does the filing include financial results or material corporate actions?

No. The Form 6-K only reports the PDMR share transaction and brand information; it does not contain earnings, major transactions, or financial tables.